Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations

A Lees,J.J Ferreira,W Poewe,H Gama,D Magalhães,J.-F Rocha,P Soares-Da-Silva

doi:10.1016/j.parkreldis.2020.06.219

Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations

A Lees, J.J Ferreira + Show 5 more

https://doi.org/10.1016/j.parkreldis.2020.06.219

Copy DOI

Journal: Parkinsonism and Related Disorders	Publication Date: Oct 1, 2020
Citations: 1

Affiliation: National Hospital for Neurology and Neurosurgery, University of Lisbon, Universität Innsbruck, Bial (Portugal), University of Porto

#Parkinson's Disease Patients #Onset Of Motor Fluctuations + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background: To evaluate the potential added benefit of opicapone (OPC), versus placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson's disease (PD) patients from the BIPARK-I trial who were recently diagnosed with motor fluctuations ('recent fluctuators'; defined as having an onset of motor fluctuations < /=1 year of study baseline).

Full Text